Form 4: Surgery Partners CEO Jason Evans Receives Restricted Stock Awards

Sentiment:

SEC Form 4 Filing


Jason Eric Evans, CEO of Surgery Partners, Inc., reports the acquisition of restricted stock awards on March 4, 2025.

Summary

  • Jason Eric Evans, the CEO of Surgery Partners, Inc., filed a Form 4 detailing changes in beneficial ownership.
  • On March 4, 2025, Evans acquired 84,033 restricted stock awards (RSAs) at a price of $23.80, which vest in three equal annual installments starting on the first anniversary of the grant date.
  • Additionally, Evans acquired 29,411 RSAs at a price of $23.80, which vest on the first anniversary of the grant date.
  • Following these transactions, Evans beneficially owns 674,142 shares of Surgery Partners, Inc. common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of RSAs is a standard practice and indicates confidence in the CEO's continued leadership. The vesting schedule promotes long-term alignment with shareholder interests.

Positives

  • The grant of restricted stock awards to the CEO aligns his interests with those of the shareholders.
  • The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSAs suggests an expectation of continued service from the CEO.

Industry Context

Grants of restricted stock are a common practice in the healthcare industry to incentivize and retain key executives. The vesting schedules are designed to align management's interests with long-term shareholder value.

Comparison to Industry Standards

  • Restricted stock awards are a common form of executive compensation in publicly traded companies, including those in the healthcare sector.
  • Companies like HCA Healthcare and Tenet Healthcare also utilize stock-based compensation to align executive incentives with shareholder returns.
  • The vesting schedules, typically ranging from one to three years, are consistent with industry norms.

Stakeholder Impact

  • Shareholders may view the grant of restricted stock as a positive sign, aligning management's interests with long-term company performance.
  • Employees may see this as a sign of stability and commitment from the leadership team.

Key Dates

DateDescription
03/04/2025Date of the restricted stock awards grant and transaction.
03/06/2025Date of the signature of the Attorney-in-Fact on the Form 4 filing.

Keywords

Surgery Partners, Jason Eric Evans, restricted stock awards, Form 4, beneficial ownership, SGRY, CEO

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.